Form 4: Director Karin Jooss Receives Stock Options

Director Karin Jooss of Fate Therapeutics was granted stock options as part of the company's director compensation policy.

Summary

• Karin Jooss, a Director at Fate Therapeutics, Inc., received a grant of stock options on June 12, 2026.
• The grant consists of 87,900 stock options with an exercise price of $2.06 per share.
• These options are exercisable starting June 12, 2026, and expire on June 12, 2036.
• The options vest on the earlier of June 12, 2027, or the date of the 2027 Annual Meeting of Stockholders, contingent on continued service.
• This grant is in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine equity grant to a director as per established compensation policy, with no immediate financial impact or significant strategic shift indicated.

Positives

• Director compensation aligns with company policy, indicating a structured approach to incentivizing board members.
• The grant of stock options provides a direct financial incentive for the director to contribute to the company's long-term success and stock performance.
• The vesting schedule encourages continued service and commitment to the company.

Risks

• The value of the stock options is directly tied to the future performance of Fate Therapeutics' stock price, which is subject to market volatility and company-specific risks.
• Continued service is a condition for vesting, meaning any departure from the board before the vesting date would result in forfeiture of the unvested options.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and the director's continued service. The options are exercisable until June 12, 2036, and vest on a staggered basis.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard practice in the biotechnology and pharmaceutical sectors, aiming to align director interests with shareholder value and attract experienced board members.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options dilutes existing share ownership slightly but aligns director incentives with long-term shareholder value creation.
• Employees: Indirect impact through the potential for increased board engagement and focus on company performance.
• Director Karin Jooss: Receives a financial incentive tied to the company's stock performance and continued service.

Next Steps

• Karin Jooss will continue her service on the Board of Directors, subject to the terms of the compensation policy.
• The stock options will vest according to the schedule outlined, contingent on continued service.
• The company will continue to operate under its Amended and Restated Non-Employee Director Compensation Policy for future equity grants.

Key Dates

Keywords

stock options, director compensation, equity grant, Fate Therapeutics, FATE, SEC Form 4, insider trading, beneficial ownership